Aptevo Therapeutics Inc.
APVO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671584
No open-market purchases or sales by Aptevo Therapeutics Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $224.3K in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Aptevo Therapeutics Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 23 | 24 | +1 |
| Shares | 760.9K | 811.9K | +51.1K (+6.7%) |
| Value | $5.99M | $4.76M | −$1.22M (−20.4%) |
New holders (5)
Institutions that held Aptevo Therapeutics Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Barclays PLC | 66,801 | $392.0K | 0.00% |
| Bank of New York Mellon Corp | 25,952 | $152.0K | 0.00% |
| Susquehanna International Group, LLP | 19,660 | $115.0K | 0.00% |
| JPMorgan Chase & Co | 204 | $1.00K | 0.00% |
| Money Concepts Capital Corp | 7 | $0 | 0.00% |
Sold out (4)
Institutions that held Aptevo Therapeutics Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| UBS Group AG | 3,212 | $25.0K |
| ACT Capital Management, LLC | 1,500 | $12.0K |
| Total Clarity Wealth Management, Inc. | 500 | $4.00K |
| Truvestments Capital LLC | 95 | $1.00K |